MADCAM1 antibody

Catalog No. ABIN2665258

The Rat Monoclonal anti-MADCAM1 antibody has been validated for FACS and CyTOF. It is suitable to detect MADCAM1 in samples from Mouse.

Quick Overview for MADCAM1 antibody (ABIN2665258)

Target: MADCAM1 (Mucosal Vascular Addressin Cell Adhesion Molecule 1 (MADCAM1))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This MADCAM1 antibody is un-conjugated

Application: Flow Cytometry (FACS), Cytometry by Time of Flight (CyTOF)

Clone: MECA-367

Product Details anti-MADCAM1 Antibody

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for MADCAM1

Target: MADCAM1 (Mucosal Vascular Addressin Cell Adhesion Molecule 1 (MADCAM1))

Alternative Name: MAdCAM-1

Background: MAdCAM-1 is a 58-66kD type I glycoprotein, also known as Mucosal addressin cell adhesion molecule-1. This mucosal vascular addressin is a member of the Ig superfamily found on fetus and neonatal endothelial cells. In adults, MAdCAM-1 is predominately expressed on high endothelial venule (HEV) of Peyer's patches, mesenteric lymph nodes and gut lamina propria. It is also expressed on vascular endothelium in mammary glands and pancreas. MAdCAM-1, through its interaction with integrin α4β7 or CD62L, is involved in lymphocyte tethering, rolling, and homing. It has been reported that immobilized MAdCAM-1 is able to co-stimulate T cell proliferation. The MECA-367 antibody blocks the interaction of MAdCAM-1 with its counter-receptor both in vitro and in vivo. In vivo administration of the mAb is able to reduce T-cell mediated inflammation in some gastrointestinal diseases.